Standing at the inflection point of a decade, the global biopharmaceutical industry is undergoing unprecedented development and transformation. Yet, the market demand remains immense, with nearly 2 billion patients worldwide facing unmet clinical needs and the persistent growing burden of non-communicable diseases serving as the core driver for biomedical innovation.

According to industry forecasts, future global biologics sales are projected to reach $1.4 trillion, increasing market share to 57%, with annual R&D investment by global pharmaceutical companies expected to exceed $300 billion.

Chinese biomedical innovation has also achieved a leapfrog evolution from "follower" to "definer." In 2025, the total value of License-out transactions by Chinese pharmaceutical companies surpassed $130 billion. Notably, China's share of global licensing deals for antibody drugs surged from 18% in 2020 to 67% in 2024.

However, innovative drug R&D is not a sprint; it is a marathon. It cannot rely solely on a flash of insight or a single breakthrough. It demands a complete systems engineering approach: from target to molecule, from process to quality, from experimentation to clinic—every step requires the support of talent, systems, and platforms.

It is for this very reason that Sanyoubio chose to build an open platform model, designed to collaborate with and empower partners to collectively accelerate the drug development process. Its focus extends beyond completing individual projects; it is concentrated on solving the fundamental challenge of generating high-quality molecules at the source, striving to create a "living source" of continuous innovation. Through constant innovation in molecular formats, it aims to exponentially improve both the quality and quantity of candidate molecules, thereby enhancing the overall success rate and efficiency of drug R&D.

Sanyoubio's philosophy is: "To make innovation not dependent on accidental luck, but on accumulative capabilities; not reliant on sporadic opportunities, but on scientific mechanisms and data-driven processes."

A decade of dedicated effort is yielding tangible results.

Sanyoubio's R&D and GMP facility footprint has expanded to over 20,000 square meters, its team has grown to more than 200 members, and it has earned over ten authoritative qualifications and recognitions, including National High-Tech Enterprise, Shanghai "Specialized, Refined, Distinctive, and Innovative" Enterprise, and Shanghai Technology Little Giant.

Operationally, its network now spans China, North America, and Europe, serving nearly 2,000 clients worldwide. It has successfully delivered over 2,000 projects, signed more than 60 collaborations. Among these partnered programs, 10 have completed IND filings, 8 are clinically active projects, and 3 have advanced into Phase III or pivotal clinical stages.

Looking back on Sanyoubio’s journey, several core pathways that have run through its growth become clear.

The company has consistently focused on the fundamental challenge in drug R&D: “How to efficiently discover high-quality source molecules.” Its solution lies in building a world-class intelligent, ultra-trillion-scale molecular library.

Since establishing its technological core in 2015, Sanyoubio has successively launched a hundred-billion-scale fully human antibody library, a ten-billion-scale single-domain naïve library, and a billion-scale common light chain library. In 2021, it completed the construction of three trillion-scale antibody libraries. Following a platform upgrade in 2022, its library capacity exceeded seven trillion; in 2023, it surpassed ten trillion, alongside the development of high-efficiency discovery platforms like "21-Day Rabbit/Canine Monoclonal Antibody" generation.

Today, Sanyoubio has entered a new phase driven by the dual engines of "AI intelligence + Trillion-scale Library." It is committed to building a generative, intelligent drug screening system, advancing toward the automated future of a "lights-out laboratory."

There is a broad industry consensus that the deep integration of AI technology and biotechnology represents the future direction of pharmaceutical R&D. Accordingly, Sanyoubio is dedicated to creating a deeply integrated "dry + wet lab" intelligent R&D platform.

This is not merely the physical combination of a "computer + benchtop." It is a fully digitalized R&D ecosystem formed by the deep convergence of computational modeling, AI optimization, and high-throughput experimental capabilities. This platform integrates multi-omics databases and various AI predictive functions, aiming to enhance the certainty and efficiency of R&D. It makes key decisions "computable, verifiable, and iterable," thereby establishing a robust mechanism of data-driven decision-making.

For any startup, balancing the pressure of survival with the construction of core competitiveness are two eternal propositions. Sanyoubio's strategy is "R&D innovation in one hand, commercial operations in the other."

Guo-Jun Lang compares R&D and business to two ends of the same value chain: one end connects to real clinical needs and market trends, the other to achievable technological pathways and molecular solutions.

Currently, Sanyoubio has incubated over 100 early-stage projects across nine major disease areas, covering oncology, autoimmunity, metabolism, and other significant therapeutic directions. This allows its platform capabilities to be continuously validated and refined through real-world projects.

Behind all of this, ultimately, are people. Sanyoubio has built a unique talent and cultural system, centered on a twelve-point cultural orientation: "Value Creation, Long-termism, People-centricity." This system defines both the competency standards and the commitment standards for its talent. Through visualized documents like the "Talent Development White Paper" and "Position & Work Blueprint," it outlines a clear growth path for every team member.

Lang believes that only by fostering an environment where top-tier talent can dedicate themselves fully to creation and continuous growth can such an ambitious mission be truly supported.

The difficulty of drug development is, in essence, an ultimate test of a company's intellectual rigor, endurance, financial strength, and conviction.

Real-world data shows that while there are over 6,800 companies globally with active R&D pipelines, the probability of breaking into the industry's top 50 is less than 1% — a stark illustration of the sector's extreme congestion and low success rates.

Even more daunting are the overall probability and cost. Even for biologics, which have relatively higher success rates, nearly 80% of projects fail between entering clinical trials and final approval. A new drug begins its journey from thousands of candidate molecules, undergoes rigorous, multi-layered screening, and only one ultimately receives approval. When accounting for the cost of failures, the median cost to successfully bring a new drug to market is a staggering $1.1 to $1.6 billion, often taking over a decade.

In Lang's view, the difficulty of novel drug R&D lies in the simultaneous pursuit of "extreme speed" and "top-tier quality" ; in the need for both "strategic focus and deep cultivation of core areas" and "self-revolution and the courage to disrupt" ; in the challenge of "drawing a grand blueprint" while "delivering on the vision to create life-saving realities."

Faced with these inherent industry challenges, a new paradigm is emerging: transforming drug development from a solitary "marathon" into a coordinated team "relay race." The core idea is to enable different capability modules, partners, and resource elements to connect seamlessly and continuously accelerate—like a baton in a relay—making each stage more specialized and efficient.

Against this backdrop, Sanyoubio has proposed the concept of building an "Original Drug Innovation Foundry."

This is not a closed laboratory, but an open, intelligent, and collaborative drug R&D ecosystem, bi-directionally driven by an "intelligent, ultra-trillion-scale molecular library" and a "dry + wet lab integrated platform." Within this system, the R&D process is deconstructed into a series of standardizable and modular functional units, enabling rapid deployment and combination at different stages.

This ecosystem aims to achieve several key objectives:

First, to construct a mutually empowering "networked ecosystem," uniting diverse entities such as pharmaceutical companies, upstream and downstream industrial chain partners, academic research institutions, clinical centers, and investment organizations. The goal is to facilitate the efficient integration of innovation elements and the conversion of value.

Second, to build a deeply open R&D platform that integrates key modules ranging from technological exploration to preclinical research. This drives an evolution in the operational model from "project services" towards "platform empowerment" and "co-creation of the ecosystem."

Ultimately, the mission is to empower global innovation partners, bridging the gap between tens of thousands of novel drug targets, global pharmaceutical companies, and the needs of billions of patients.

As a key recent initiative to put its vision into practice, Sanyoubio is driving its "Double Five Plan" through the dual engine of its AI-powered Super Trillion Antibody Library (AI-STAL) and the Original Drug Innovation Foundry. By leveraging its platform to lower marginal costs and standardization to enhance delivery efficiency, the company ultimately aims to amplify the overall success rate of innovation through ecosystem synergies.

Ten years to forge a sword, now setting forth anew.

Sanyoubio's decade has been ten years of resonating with China's biomedical innovation, ten years of evolving from technological exploration to ecosystem construction, and ten years of steadfastly adhering to its original aspiration and continuous deep cultivation. Standing at the starting point of a new decade, the global wave of biopharmaceutical innovation has arrived, and Chinese innovation is advancing toward the world with a renewed posture.

"Making innovative biologics accessible to all" is no longer merely a mission statement of a single company. It is becoming a new chapter—co-authored by an entire ecosystem—about life and the future. From this day forward, every day is the first day of this new journey.